• 1997-2004   芝加哥大学  博士

• 1992-1995   北京医科大学  硕士

• 1988-1992   安徽大学    学士

• 2023-至今   上海交通大学张江高等研究院

                        上海交通大学转化医学研究院

                        世界顶尖科学家国际联合实验室

• 2018-2022   上海市瑞金医院

• 2013-2017   哈佛医学院麻省总院

• 2006-2012   哈佛医学院但那法波肿瘤研究所

• 2004-2005   麻省理工学院生物系

• 从事新药创制和皮肤生物学研究，尤其是开发蛋白激酶抑制剂，并以此为化学探针，破译细胞信号网络，探索肿瘤耐药成因，以及皮肤干细胞自然演化和衰老机制。既往在Nature, Cancer Research等期刊上发表了86篇论文, (https://scholar.google.com/citations?user=N7qEFL4AAAAJ),引用总次数超过13,800，H-index=41，拥有6项国际授权专利。发明的化合物如GNF-5，Torin1等被广泛用于学术研究。是推进BCR-ABL变构抑制剂，新型慢性粒细胞性白血病临床用药Asciminib（诺华）研发的主要贡献人。在研的针对临床耐药的四代EGFR抑制剂于2022年进入临床实验。

• 欢迎对创新药物研发有兴趣的科研人员，可申请研究助理，博士后，或者博士研究生来加入我们。Together，we can do more.

• 研究课题受到国家自然科学基金重大项目，面上项目，上海市科委，药企新药研发项目支持。

Gq/11 and Eye cancer：

• Li Y, Zhu T, Yang J, Zhang Q, Xu S, Ge S, Jia R*, Zhang J*, Fan X.* EHMT2 promotes tumorigenesis in GNAQ/11-mutant uveal melanoma via ARHGAP29-mediated RhoA pathway. Acta Pharm Sin B. 2024;14(3):1187-1203

• Li Y, Yang J, Zhang Q, Xu S, Sun W, Ge S, Xu X, Jager MJ, Jia R*, Zhang J*, Fan X.* Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma. Oncogene. 2022;41(27):3539-3553

• Zhang Y, Zhang B, Li Y, Dai Y, Li J, Li D, Xia Z, Zhang J, Liu P, Chen M, Jiao B, Ren R. Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma. Front Med. 2022;16(5):784-798

• Yang J, Li Y, Zong C, Zhang Q, Ge S, Ma L, Fan J, Zhang J*, Jia R*. Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle. Invest. Ophthalmol. & Vis. Sci. 2021:62 (15):11

• Li Y, Shi J, Yang J, Ge S, Zhang J, Jia R, Fan X. Uveal melanoma: progress in molecular biology and therapeutics. Ther Adv Med Oncol. 2020 Oct 22;12:1758835920965852

BRK in Breast cancer:

• Jiang J, Gui F, He Z, Li L, Li Y, Li S, Wu X, Deng Z, Sun X, Huang X, Huang W, Han S, Zhang T, Wang Z, Jiao B, Song S, Wang H, Chen L, Zhou D, Liu Q, Ren R*, Zhang J*, Deng X*. Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors. Cancer Res. 2017; 77(1):175-186

ALK inhibitors:

• Lu Y, Fan Z, Zhu SJ, Huang X, Zhuang Z, Li Y, Deng Z, Gao L, Hong X, Zhang T, Li L, Sun X, Huang W, Zhang J, Liu Y, Zhang B, Jiang J, Gui F, Wang Z, Li Q, Song S, Huang X, Wu Q, Chen L, Zhou D, Zhang J*, Yun CH*, Chen L*, Deng X*. A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. EMBO Mol Med. 2022 14(1):e14296

• Deng D*, Wang J*, Zhang J*, Sim T, Kim ND, Sasaki T, Luther WII, George R, Jänne PA, and Gray NS, Discovery of 3,5-diamino-1,2,4-triazole-ureas as potent Anaplastic Lymphoma Kinase (ALK) inhibitors. ACS Med Chem Lett. 2011;2(5):379-38

• Deng X, Lim SM, Zhang J, Gray NS. Broad Spectrum Alkynyl inhibitors of T315I Bcr-Abl. Bioorg.  Med. Chem. Lett. 2010;20(14):4196-200

• George RE*, Sanda T*, Hanna M*, Fröhling S, Luther W, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L. Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature,2008;455(7215):975-8

BTK inhibitors:

• Gui F, Jiang J, He Z, Li L, Li Y, Deng Z, Lu Y, Wu X, Chen G, Su J, Song S, Zhang YM, Yun CH, Huang X, Weisberg E, Zhang J*, Deng X*. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies. Br J Pharmacol. 2019;176(23):4491-4509

Pharmacology of ABL kinase:

• Zhang J*, Adrián FJ*, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers P, Dierks C, Sun F, Guo G, Ding Q, Okram B, Choi Y, Wojciechowski AL, Deng X, Liu G, Fendrich G, Strauss A, Vajpai N, Grzesiek S, Tuntland T, Liu Y, Bursulaya B, Azam M, Manley PW, Engen JR, Daley GQ, Warmuth M, Gray NS. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature, Article, 2010;463:501-506

• Iacob RE, Zhang J, Gray NS, Engen JR. Allosteric effects within the Abl kinase upon non-ATP competitive inhibitor binding PLoS ONE  2011;6(1):e15929

• Deng X*, Okram B*, Ding P*, Zhang J*, Choi Y, Adrián FJ, Wojciechowski AL, Zhang G, Bursulaya B, Sim T, Gray NS., Expanding the diversity of allosteric Bcr-abl inhibitors. J. Med. Chem. 2010;53(19):6934-46

• Deng X, Lim SM, Zhang J, Gray NS. Broad Spectrum Alkynyl inhibitors of T315I Bcr-Abl. Bioorg.  Med. Chem. Lett. 2010;20(14):4196-200

• Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, Gray NS and Sim T. A Type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl. J Med Chem. 2010;53 (15):5439-48

• Weisberg E*, Choi HG*, Ray A*, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Mayeda M, Fletcher J, Debiec-Rychter M, Mayeda M., Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley P, Adamia S, Wu C, Gray NS and Griffin JD Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood 2010;115(21):4206-16

• Fabbro D, Manley PW, Jahnke W, Liebetanz J, Szyttenhiolm A, Fendrich G, Strauss A, Zhang J, Gray NS, Adrian F, Warmuth M, Pelle X, Grotzfeld R, Berst F, Marzinzik A, Cowan-Jacob SW, Mestan J. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding. Biochim Biophys Acta 2010;1804(3):454-462

• Iacob RE, Dumitrescu TP, Zhang J, Gray NS, Smithgall TE & Engen JR. Conformational disturbance in Abl kinase upon mutation and deregulation.  Proc Natl Acad Sci USA. 2009;106(5):1386-91

*: equal contribution